Advanced search
Publication Cover
Expert Review of Ophthalmology Volume 7, 2012 - Issue 3
Submit an article Journal homepage
50
Views
7
CrossRef citations to date
0
Altmetric
Review

Consensus on the diagnosis, treatment and follow-up of patients with age-related macular degeneration eligible for ranibizumab

Alfredo Pece Department of Ophthalmology, Melegnano Hospital, Milan, Italy. [email protected]; Department of Ophthalmology, Melegnano Hospital, Milan, Italy. [email protected]
,
Claudio Azzolini Department of Morphological & Surgical Sciences, Division of Ophthalmology, University of Insubria, Varese, Italy; Department of Morphological & Surgical Sciences, Division of Ophthalmology, University of Insubria, Varese, Italy
,
Maurizio Battaglia Parodi Department of Ophthalmology, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy; Department of Ophthalmology, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy
,
Ferdinando Bottoni Eye Clinic, Department of Clinical Science “Luigi Sacco”, Sacco Hospital, University of Milan, Milan, Italy; Eye Clinic, Department of Clinical Science “Luigi Sacco”, Sacco Hospital, University of Milan, Milan, Italy
,
Paola Danzi Department of Ophthalmology, Spedali Civili Hospital, Brescia, Italy; Department of Ophthalmology, Spedali Civili Hospital, Brescia, Italy
,
Simone Donati Department of Morphological & Surgical Sciences, Division of Ophthalmology, University of Insubria, Varese, Italy; Department of Morphological & Surgical Sciences, Division of Ophthalmology, University of Insubria, Varese, Italy
,
Ugo Introini Department of Ophthalmology, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy; Department of Ophthalmology, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy
,
Vincenzo Pucci Department of Ophthalmology, Desenzano del Garda Hospital, Desenzano del Garda, Italy; Department of Ophthalmology, Desenzano del Garda Hospital, Desenzano del Garda, Italy
,
Francesco Semeraro Department of Ophthalmology, Spedali Civili Hospital, Brescia, Italy; Department of Ophthalmology, Spedali Civili Hospital, Brescia, Italy
&
Francesco Viola University of Milan, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy; University of Milan, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy
 show all
Pages 219-225 | Published online: 09 Jan 2014

References

  • Gaudreault J, Fei D, Rusit J et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci.46, 726–733 (2005).
  • Rosenfeld PJ, Heier JS, Hantsberger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology13(4), 623–632 (2006).
  • Heier JS, Antoszyk AN, Pavan PR et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a Phase I/II multicenter, controlled, multidose study. Ophthalmology113(4), 633–642 (2006).
  • Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med.355, 1419–1431 (2006).
  • Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus Verteporfin photodynamic therapy for neovascular macular degeneration. N. Engl. J. Med.355, 1432–1444 (2006).
  • Regillo CD, Brown DM, Abraham P et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am. J. Ophthalmol.145, 239–248 (2008).
  • Massacesi AL, Sacchi L, Bergamini F, Bottoni F. The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization. Graefe’s Arch. Clin. Exp. Ophthalmol.246, 89–92 (2008).
  • Mitchell P, Korobelnik JF, Lanzetta P et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br. J. Ophthalmol.94, 2–13 (2010).
  • Brown DM, Michels M, Kaiser PK et al. Ranibizumab versus Verteporfin photodynamic therapy for neovascular macular degeneration: two-year results of the ANCHOR study. Ophthalmology116, 57–65 (2009).
  • Schmidt-Erfurth U, Eldem B, Guymer R et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology118, 831–839 (2011).
  • Abraham P, Yue H, Wilson L et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 2. Am. J. Ophthalmol.150, 315–324 (2010).
  • Fung AE, Lalwani GA, Rosenfeld PJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration. Am. J. Ophthalmol.143, 566–583 (2007).
  • Lalwani GA, Rosenfeld PJ, Fung AE et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am. J. Ophthalmol.148, 43–58 (2009).
  • Holz FG, Amoaku W, Donate JD et al. Safety and efficacy of flexible dosing regimen of ranibizumab in neovascular age-related degeneration: the SUSTAIN study. Ophthalmology118, 663–671 (2011).
  • Kaiser PK, Brown DM, Zhang K et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: sub-group analysis of first year ANCHOR results. Am. J. Ophthalmol.144, 850–857 (2007).
  • Boyer DS, Antoszyk AN, Awh CC et al. Sub-group analysis of the MARINA study of ranibizumab in neovascular age-related macula degeneration. Ophthalmology114, 246–252 (2007).
  • Kaiser PK, Blodi BA, Shapiro H et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology114, 1868–1875 (2007).
  • Amoaku WM. The royal college of ophthalmologists interim recommendations for the management of patients with age-related macular degeneration. Eye22, 864–868 (2008).
  • Amoaka WM. Ranbizumab: the clinician’s guide to commencing, continuing, and discontinuing treatment. Eye23, 2140–2142 (2009).
  • Boyer DS, Heier JS, Brown DM et al. A Phase III study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology116(9), 1731–1739 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.